Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Summary

The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD). The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.

Timeline

Start

2019-10-15

Primary completion

2022-09-21

Completion

2023-01-17

Drugs

Indications